Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease (2026)

Peer-Reviewed Study · Wischik CM, Stefanacci R, Bentham P, Gauthier S, Zetterberg H, Wilcock GK, et al. · January 21, 2026

Wischik CM et al., 2026-01-21: Peer-reviewed publication of LUCIDITY (NCT03446001), the 598-patient phase 3 trial of hydromethylthionine mesylate 16 mg/day: the 52-week co-primary clinical endpoints were not met, and the authors attribute this to symptomatic activity of the low-dose methylthioninium chloride control; positive findings are confined to biomarkers and to an MCI subgroup at 78-104 weeks.

It was not possible to demonstrate significant differences on the co-primary clinical endpoints (ADAS-cog11 and ADCS-ADL23) at 52 weeks due to symptomatic activity in the control arm.

Wischik CM et al., 2026-01-21: Peer-reviewed publication of LUCIDITY (NCT03446001), the 598-patient phase 3 trial of hydromethylthionine mesylate 16 mg/day: the 52-week co-primary clinical endpoints were not met, and the authors attribute this to symptomatic activity of the low-dose methylthioninium chloride control; positive findings are confined to biomarkers and to an MCI subgroup at 78-104 weeks. Study type: randomised, double-blind, delayed-start phase 3 with open-label extension, 82 centres in Canada, EU, UK and USA. N=598, all amyloid PET positive (263 MCI-AD, 335 mild-moderate AD). Drug: hydromethylthionine mesylate (HMTM, TRx0237/LMTM) 16 mg/day or 8 mg/day oral, versus control methylthioninium chloride 4 mg twice WEEKLY 'intended as an inactive urinary colourant'. 52 weeks blinded then all on 16 mg/day to 104 weeks. Funder: TauRx (majority of authors TauRx employees). Epub 2026-01-21. Authors' own conclusion: 'symptomatic activity in the control arm precluded separation of treatment arms at 52 weeks on primary clinical endpoints.' Reported p-values cited (0.0291, 0.0308, 0.0165) are for biomarker and MCI-subgroup analyses specified before the 24-month database lock, not for the co-primary endpoints. Also filed as MTD-072, MTK-21, MTC-075 (claims C11, C3, C5). Study type: randomized trial.